Pacific Edge | PEB

Stock Price
0.14
Daily Change
-0.001 -0.70%
Monthly
41.00%
Yearly
38.24%
Q3 Forecast
0.14

Peers Price Chg Day Year Date
Avita Medical 1.34 0.01 0.75% -48.46% Sep/05
Paradigm Biopharmaceuticals 0.28 0.02 5.66% 19.15% Sep/05
Pacific Edge 0.14 -0.001 -0.70% 38.24% Sep/05
PYC Therapeutics 1.25 -0.02 -1.57% 8.70% Sep/05
Telix Pharmaceuticals 13.80 0.03 0.22% -22.21% Sep/05

Indexes Price Day Year Date
NZX 50 13224 90.33 0.69% 4.82% Sep/05

Pacific Edge traded at 0.14 this Friday September 5th, decreasing 0.001 or 0.70 percent since the previous trading session. Looking back, over the last four weeks, Pacific Edge lost 41.00 percent. Over the last 12 months, its price rose by 38.24 percent. Looking ahead, we forecast Pacific Edge to be priced at 0.14 by the end of this quarter and at 0.14 in one year, according to Trading Economics global macro models projections and analysts expectations.

Pacific Edge Limited is a cancer diagnostics company. The Company develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The Company's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. It offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.